| 00:00:00 | Welcome |
| 00:01:30 | NTA Provides: |
| 00:02:08 | What I will cover today |
| 00:03:04 | Optical Arrangement for NanoSight Instruments |
| 00:04:15 | Particles are visualized, not imaged |
| 00:04:15 | Sizing: Stokes-Einstein |
| 00:05:35 | Concentration: Particles are Counted by Number |
| 00:05:35 | The biological significance of the protein corona |
| 00:06:38 | Nanoparticles are Exposed To Serum Proteins Upon Exposure to the Blood |
| 00:07:22 | The protein corona determines biological fate |
| 00:08:26 | Using a protein corona predictive model to predict biological fates. |
| 00:09:41 | Their Results and Conclusions |
| 00:10:51 | Examples: NTA data for Gold Nanorods dispersed in protein solutions. |
| 00:11:40 | Human Serum Albumin Coated Gold Nanorods |
| 00:12:51 | Citrate coated Gold Nanorods dispersed in fetal bovine serum |
| 00:14:02 | PEG coated Gold Nanorods dispersed in FBS |
| 00:15:30 | Example 2: Investigating analytical tools to measure protein conjugated nanoparticles: DLS and NTA. |
| 00:17:29 | Example 3: On-line protein corona characterization using SEC, MALS, NTA, ICP-MS |
| 00:18:23 | Protein corona conclusions |
| 00:18:59 | Human Serum Albumin as an Excipient Background |
| 00:20:08 | HSA properties cont. |
| 00:20:57 | Abraxane (nab-Paclitaxel), Albumin-bound paclitaxel. |
| 00:22:48 | Recent and exciting advances in albumin drug formulations. |
| 00:23:59 | Example 1 |
| 00:25:14 | Example 2 |
| 00:26:04 | Example 3 |
| 00:26:49 | Example 4 |
| 00:27:23 | Example 5 |
| 00:28:23 | 2nd generation albumin drug formulations |
| 00:28:44 | Example 6 |
| 00:29:48 | Example 7 |
| 00:30:43 | Example 8 |
| 00:31:47 | NTA Size and Particle Counts |
| 00:32:53 | A rapidly advancing field… |
| 00:33:53 | Conclusions |
| 00:35:13 | Thank you for your attentionAny questions? |
| 00:40:56 | Contact Information |
This webinar introduces the Nanoparticle Tracking Analysis (NTA) technique and discusses how it can provide a range of useful characterization information for protein corona and self-assembled albumin-drug nanoparticles. Reviews of the latest literature for both protein corona and self assembled albumin-drug nanoparticles are presented. Finally, examples of NTA being used to characterize the size and counts of the protein corona and albumin-drug nanoparticles are shown.